|
| REVIEW ARTICLE |
 |
|
|
| Year : 2013 |
Volume
: 6 | Issue : 2 | Page
: 93-98 |
|
Current evidence supporting "letrozole" for ovulation induction
Sujata Kar
Department of Obstetrics and Gynecology, Kar Clinic and Hospital Pvt. Ltd, Bhubaneswar, Odisha, India
Correspondence Address:
Sujata Kar
Department of Obstetrics and Gynecology, Kar Clinic and Hospital Pvt. Ltd, Bhubaneswar, Odisha - 751 001
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0974-1208.117166
|
|
|
Aromatase inhibitor "letrozole" was first introduced as a potential ovulation induction (OI) drug almost a decade back. Large number of studies has been published using letrozole for OI: In polycystic ovary syndrome (PCOS) women, clomiphene citrate (CC) resistant women, for intrauterine insemination and also in various protocols of mild stimulation for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). Letrozole appears to be a good option, with its oral route of administration, cost, shorter half-life and negligible side effects. However, the verdict on efficacy and safety of letrozole is still uncertain. This review explores the current scientific data supporting letrozole for OI. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
|
|
